Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

First Posted Date
2018-11-23
Last Posted Date
2021-06-30
Lead Sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Target Recruit Count
31
Registration Number
NCT03751176
Locations
🇪🇸

ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain

🇪🇸

Hospital de Granollers, Granollers, Barcelona, Spain

🇪🇸

Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain

and more 15 locations

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

First Posted Date
2018-11-20
Last Posted Date
2023-10-24
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
746
Registration Number
NCT03748134
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇦🇺

Austin Hospital, Heidelberg, Victoria, Australia

🇧🇪

Cliniques Universitaires Saint-Luc Av., Bruxelles, Hippocrate 10, Belgium

and more 44 locations

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

First Posted Date
2018-11-09
Last Posted Date
2023-12-19
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
11
Registration Number
NCT03736720
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

Stony Brook Cancer Center, Stony Brook, New York, United States

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

First Posted Date
2018-11-06
Last Posted Date
2018-11-06
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
30
Registration Number
NCT03732508
Locations
🇨🇳

Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

First Posted Date
2018-10-26
Last Posted Date
2023-10-12
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
218
Registration Number
NCT03721653
Locations
🇮🇹

Francesca Vannini, Pisa, Italia, Italy

Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

First Posted Date
2018-10-23
Last Posted Date
2024-12-12
Lead Sponsor
Inhibrx Biosciences, Inc
Target Recruit Count
321
Registration Number
NCT03715933
Locations
🇺🇸

Precision NextGen Oncology and Research, Beverly Hills, California, United States

🇺🇸

University of California, San Francisco (UCSF), San Francisco, California, United States

🇺🇸

Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States

and more 31 locations

The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

First Posted Date
2018-10-18
Last Posted Date
2019-03-13
Lead Sponsor
National Cheng-Kung University Hospital
Target Recruit Count
40
Registration Number
NCT03711240
Locations
🇨🇳

National Cheng-Kung University Hospital, Tainan, Taiwan

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

First Posted Date
2018-10-11
Last Posted Date
2021-01-27
Lead Sponsor
Benaroya Research Institute
Target Recruit Count
30
Registration Number
NCT03703063
Locations
🇺🇸

Virginia mason medical Center, Seattle, Washington, United States

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

First Posted Date
2018-10-09
Last Posted Date
2024-01-31
Lead Sponsor
Asan Medical Center
Target Recruit Count
20
Registration Number
NCT03698461
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

First Posted Date
2018-10-03
Last Posted Date
2024-07-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
35
Registration Number
NCT03693807
Locations
🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Commack, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy